J&J's Innovative Medicine Unit Proves Its Resilience in Q2

JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.

Zacks Investment Research • Jul 24, 2026

3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives

Baby boomers heading into retirement face a specific math problem: They need income that grows faster than inflation, drawn from businesses stable enough to survive whatever the next decade throws at them.

24/7 Wall Street • Jul 24, 2026

Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher

Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.

Zacks Investment Research • Jul 24, 2026

ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook

Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.

Zacks Investment Research • Jul 23, 2026

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the company's leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey RARITAN, N.J., July 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and TALVEY® + pomalidomide in adult patients with relapsed or refractory multiple myeloma (RRMM) who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide.1 The study demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival for both investigational arms compared with investigator's choice standard of care.

PRNewsWire • Jul 23, 2026

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Johnson & Johnson said ​on Wednesday the U.S. ‌Food and Drug Administration had granted marketing authorization ​for its robotic surgery ​device, clearing the way ⁠for the healthcare conglomerate ​to enter the soft-tissue ​robotic surgery market.

Reuters • Jul 22, 2026

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

A federal judge cast doubt on Wednesday on claims by approximately 69,000 people alleging that Johnson & Johnson's baby powder and ​other talc products caused ovarian cancer, saying plaintiffs must provide ‌more specific evidence or risk having their lawsuits dismissed.

Reuters • Jul 22, 2026

FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System

The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson's (NYSE:JNJ) OTTAVA Robotic Surgical System, marking the regulatory clearance of the world's first table-integrated soft tissue robotic platform.

Benzinga • Jul 22, 2026

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Jul 22, 2026

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world's first table-integrated soft tissue robotic system. The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesio.

Business Wire • Jul 22, 2026